Source link : https://www.newshealth.biz/health-news/novel-tki-promising-in-early-study-of-her2-mutant-nsclc/
The investigational tyrosine kinase inhibitor (TKI) BAY 2927088 induced responses in previously treated HER2-mutant non-small cell lung cancer (NSCLC) and had a favorable safety profile, according to phase I data presented at the American Society of Clinical Oncology (ASCO) annual meeting. In this MedPage Today video, Nicolas Girard, MD, PhD, of Institut Curie in Paris, […]
Author : News Health
Publish date : 2024-06-28 14:05:52
Copyright for syndicated content belongs to the linked Source.
Categories